While a rearrangement of the MYC oncogene has been widely recognized as a negative prognostic factor in advanced-stage (III–IV) DLBCL, its impact in limited-stage (I–II) DLBCL remains unclear. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.